Related Experiment Video
Updated: May 22, 2025

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis
Published on: February 9, 2021
[Gender Disparities in Urolithiasis with a Special Focus on Oxalate Metabolism in the Liver]
Roman Herout1, Sven Oehlschläger1
1Klinik und Poliklinik für Urologie, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany.
Abstract:
The incidence and prevalence of urolithiasis are increasing in industrialized countries. In particular, an increase has been observed among young adults and women. The gender gap is closing, and gender equality (1:1) with regard to urolithiasis has already been documented for the USA. Studies have demonstrated that women have higher urine pH values than men, which promotes calcium phosphate crystallization. The tendency for men to develop calcium oxalate and uric acid stones is caused by the comparatively lower urine pH values. Malnutrition combined with a lack of exercise and the occurrence of metabolic syndrome with its underlying diseases (insulin resistance, type 2 diabetes mellitus, obesity, dyslipidaemia) are discussed as the causes of the increase in upper tract stone disease in industrialized countries. Non-alcoholic fatty liver disease (NAFLD), as the most common liver disease, is considered one of the complications of metabolic syndrome, with a prevalence of approximately 23% in Germany. Animal experiments and clinical studies have demonstrated a connection between NAFLD and increased oxalate excretion in urine. Based on the literature, NAFLD represents a possible cross-gender risk factor for kidney stone formation and is therefore considered to be a generally modifiable risk factor for recurrent urolithiasis. Simple recommendations concerning NAFLD should complement the general and metabolic workup in everyday clinical practice.
Related Concept Videos
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Hepatic Drug Excretion: Influencing Factors
Phase I Oxidative Reactions: Overview
Hepatic Drug Clearance: Role of Transporters
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...

